March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Genetic Inactivation of Aldose Reductase does not prevent ERG deficits associated with STZ-induced Diabetes
Author Affiliations & Notes
  • Ivy S. Samuels
    Research Service, Louis Stokes VA Medical Center, Cleveland, Ohio
    Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Chieh Allen Lee
    Department of Medicine, Case Western Reserve University, Cleveland, Ohio
  • Gwen M. Sturgill-Short
    Research Service, Louis Stokes VA Medical Center, Cleveland, Ohio
    Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • J. Mark Petrash
    Department of Ophthalmology, University of Colorado, Denver, Colorado
  • Neal S. Peachey
    Research Service, Louis Stokes VA Medical Center, Cleveland, Ohio
    Ophthalmic Research, Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio
  • Timothy S. Kern
    Research Service, Louis Stokes VA Medical Center, Cleveland, Ohio
    Department of Medicine, Case Western Reserve University, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  Ivy S. Samuels, None; Chieh Allen Lee, None; Gwen M. Sturgill-Short, None; J. Mark Petrash, None; Neal S. Peachey, None; Timothy S. Kern, None
  • Footnotes
    Support  Department of Veterans Affairs; Foundation Fighting Blindness; Research to Prevent Blindness; R01 EY005856; and R01 EY00300.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 4653. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ivy S. Samuels, Chieh Allen Lee, Gwen M. Sturgill-Short, J. Mark Petrash, Neal S. Peachey, Timothy S. Kern; Genetic Inactivation of Aldose Reductase does not prevent ERG deficits associated with STZ-induced Diabetes. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4653.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : We have previously reported (ARVO 2011) that streptozotocin (STZ)-induced diabetes elicits reductions in the amplitude of specific components of both the dc- and standard ERG waveforms. Aldose reductase (AR) is the first enzyme required in the polyol-mediated metabolism of glucose, and others have reported that AR inhibitors improve diabetes-induced ERG defects. Here, we used control and AR-/- mice to determine if genetic inactivation of this enzyme prevents retinal electrophysiologic defects observed in a mouse model of type 1 diabetes.

Methods: : All mice studied (WT or AR-/-) were of the C57BL/6J strain. STZ was used to induce hyperglycemia and type 1 diabetes. Diabetic and age-matched non-diabetic controls of each genotype were maintained for 22 weeks; diabetics were treated with suboptimal doses of insulin to prevent body weight loss but not prevent hyperglycemia. ERG-based techniques were used to measure the light-evoked components of the RPE (dc-ERG) and the neural retina (a-wave, b-wave).

Results: : In comparison to non-diabetic controls, both WT and AR-/- diabetic mice displayed significant decreases in the c-wave (WT=1.18; AR-/- =1.36; WTdiab=0.64; AR-/-diab=0.56 mV), fast oscillation (WT=1.43; AR-/- =1.62; WTdiab=0.87; AR-/-diab=0.75 mV), and off response (WT= -0.73; AR-/- = -0.83; WTdiab= -0.32; AR-/-diab= -0.33 mV) of the dc-ERG. Non-diabetic AR-/- mice displayed larger ERG component amplitudes than did non-diabetic WT mice, however, the amplitude of dc-ERG components in diabetic AR-/- animals were similar to WT diabetics. ERG a-wave amplitudes were not reduced in either diabetic group (e.g. in response to 1.38 log (cd s/m2): WT=313.4; AR-/- =379.3; WTdiab=310.8; AR-/-diab=329.5 μV), but b-wave amplitudes were modestly lower in WT and AR-/- diabetic mice (e.g. in response to 1.38 log (cd s/m2): WT=576.3; AR-/- =740.1; WTdiab=479.2; AR-/-diab=518.6 μV).

Conclusions: : Electrophysiologic evaluation shows that function of the RPE and retina are disrupted in the STZ-induced mouse model of type 1 diabetes, and these defects are not ameliorated by deletion of AR. This finding suggests that benefits observed in the ERG following pharmacological inhibition of AR were secondary to off-target effects of the drugs.

Keywords: diabetes • electroretinography: non-clinical 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×